Offer - Urjas Oil for just ₹ 1
Tenlimac M 1000 Tablet SR is a prescription medicine that is available as a Tablet. Secondary and off-label uses of Tenlimac M 1000 Tablet SR have also been mentioned below.
The correct dosage of Tenlimac M 1000 Tablet SR depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
Common side effects of Tenlimac M 1000 Tablet SR include Stomach Upset, Difficulty urinating, Hypoglycemia (Low blood sugar level). Besides the aforementioned side effects, there are other adverse effects of Tenlimac M 1000 Tablet SR as well, which are listed below. Normally, these side effects of Tenlimac M 1000 Tablet SR are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
It is also important to note that Tenlimac M 1000 Tablet SR has a Moderate effect for pregnant women and Severe effect on lactating mothers. Further, the section on Tenlimac M 1000 Tablet SR related warnings talks about Tenlimac M 1000 Tablet SR's effects on the liver, heart and kidney.
Tenlimac M 1000 Tablet SR is contraindicated in people with pre-existing medical conditions like Congestive Heart Failure (CHF), Anemia, Shock as it can result in adverse effects. Some other conditions that can be affected by Tenlimac M 1000 Tablet SR are listed in the contraindications section below.
Drug reaction of Tenlimac M 1000 Tablet SR with other medicines has been reported. A complete list of these interactions is given below.
You should also be aware that Tenlimac M 1000 Tablet SR is safe while driving, and is addiction.
Tenlimac M 1000 Tablet SR is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Tenlimac M 1000 Tablet SR safe for pregnant women?
Tenlimac M can have harmful effects in pregnant women. If you experience any discomfort after using Tenlimac M, then discontinue the use and take your doctor's advice.
Is the use of Tenlimac M 1000 Tablet SR safe during breastfeeding?
Taking Tenlimac M may lead to serious side effects if you are breastfeeding. Tenlimac M should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Tenlimac M 1000 Tablet SR on the Kidneys?
There is no research available on the side effects of Tenlimac M on kidney. Therefore, its impact is unknown.
What is the effect of Tenlimac M 1000 Tablet SR on the Liver?
Information about safety of Tenlimac M for the liver is not available since scientific research on this is yet to be done.
What is the effect of Tenlimac M 1000 Tablet SR on the Heart?
Side effects of Tenlimac M on heart are unknown because research on this has not been conducted yet.
If you are suffering from any of the following diseases, you should not take Tenlimac M 1000 Tablet SR unless your doctor advises you to do so -
Is this Tenlimac M 1000 Tablet SR habit forming or addictive?
No, you will not get addicted to Tenlimac M 1000 Tablet SR.
Interaction between Food and Tenlimac M 1000 Tablet SR
There isn't any research available on the side effects of taking Tenlimac M 1000 Tablet SR with food.
Interaction between Alcohol and Tenlimac M 1000 Tablet SR
It is difficult to say anything about the effect of Tenlimac M 1000 Tablet SR and alcohol. No research has been done on this yet.
Yes, Tenlimac M can cause night sweat, the exact mechanism of sweating is not known. But some research suggests that Tenlimac M causes hypoglycemia (low blood sugar) especially at night which can cause night sweats. Need to monitor your blood glucose level regularly, and talk to your doctor as your dose of Tenlimac M may need to be adjusted.
Tenlimac M should be taken with food to reduce stomach and bowel side effects, which may experience the first few weeks of treatment. Also, exercise regularly and test for sugar in your blood or urine as directed.
Tenlimac M helps in weight loss by reducing appetite and food intake. It also increases the insulin sensitivity in your body to work more effectively. This lead to decreased glucose production increases the use of glucose and decrease the fat deposition further helps in weight loss. However, Tenlimac M is not approved for weight loss, this is an off-label use.
Lactic acidosis associated with Tenlimac M treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Tenlimac M induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst.
Yes, Tenlimac M can cause some sleep problems, especially insomnia. On the other hand, Tenlimac M has proven to be useful for preventing sleep apnea. The exact relationship between Tenlimac M and sleep problems is still not clear, and further studies are needed for a clearer understanding.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826